Shnehal Patel, MD
Neurology · Grove City, OHNPI 1972820447
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $163,076 of the $198,174 with a category attached, or 82.3%. AbbVie accounts for 64.0% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $57,511, 2.2 times the $25,704 reported in 2019. Among neurology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 360 payments — averaging $550.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$127K
- MDD US Operations, LLC$22K
- Kyowa Kirin, Inc.$15K
- Amneal Pharmaceuticals LLC$10K
- Adamas Pharmaceuticals, Inc.$8K
- Neurocrine Biosciences, Inc.$6K
- plus $10K from 9 others
What the payments were for
- Consulting fees$6,6753%
- Speaking & faculty fees$163,07682%
- Travel & lodging$20,92011%
- Food & beverage$6,1703%
- Education$1,3331%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 216 | $126,895 |
| MDD US Operations, LLC | 25 | $22,386 |
| Kyowa Kirin, Inc. | 18 | $15,127 |
| Amneal Pharmaceuticals LLC | 25 | $10,324 |
| Adamas Pharmaceuticals, Inc. | 4 | $7,680 |
| Neurocrine Biosciences, Inc. | 9 | $5,760 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $5,547 |
| Medtronic | 18 | $1,635 |
| Abbott | 13 | $1,507 |
| Boston Scientific | 9 | $841 |
| Teva Pharmaceuticals USA, Inc. | 7 | $273 |
| Acorda Therapeutics, Inc | 1 | $88 |
| Insightec,inc | 1 | $84 |
| Baxter Healthcare | 1 | $14 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Duopa$64,138
- VYALEV$47,993
- GOCOVRI$27,530
- NOURIANZ$14,842
- ONGENTYS$13,208
- UBRELVY$9,928
- NURTEC ODT$5,482
- QULIPTA$2,638
- INFINITY$1,086
- PERCEPT PC BRAINSENSE$930
- GENERAL DBS$616
- INGREZZA$121
How this compares
$198,174 in reported general payments places this provider in the 90th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 31 | $241,544 |
| AustedoDeutetrabenazine | 15 | $188,616 |
| Austedo XrDeutetrabenazine | 23 | $157,350 |
| GocovriAmantadine Hcl | 14 | $42,819 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 623 | $22,955 |
| RytaryCarbidopa/Levodopa | 27 | $15,771 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 218 | $12,643 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $8,868 |
| Rivastigmine | 44 | $8,290 |
| Primidone | 199 | $5,141 |
| Droxidopa | 12 | $3,328 |
| Selegiline Hcl | 16 | $1,773 |
| AmantadineAmantadine Hcl | 35 | $1,743 |
| Ropinirole ErRopinirole Hcl | 12 | $1,228 |
| Propranolol Hcl ErPropranolol Hcl | 34 | $1,176 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $273 | $345,96638 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $5,760 | $241,54431 claims |
| MDD US Operations, LLCGocovri | $22,386 | $42,81914 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $10,324 | $16,28345 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 702 neurology providers in Ohio.
Other neurology in Grove City
- Aram ZabetiCincinnati$1.6M
- Kenneth MankowskiColumbus$1.4M
- Aaron BosterColumbus$1.2M
- Martin TaylorNew Albany$821K
- Jacqueline NicholasColumbus$743K
- Lawrence ElmerToledo$687K
- Kenneth PugarCenterville$582K
- Brendan BauerSheffield Village$548K
- Geoffrey EubankColumbus$508K
- Lawrence GoldstickDayton$479K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.